Andrey Seluzhitskiy, MD
Family Medicine · New Carlisle, INNPI 1568452902
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $28,352 of the $36,953 with a category attached, or 76.7%. It is spread thinly across 60 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $11,927, 2.8 times the $4,267 reported in 2019. Among family medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,405 payments — averaging $26.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Verity Pharmaceuticals Inc.$7K
- Viiv Healthcare Company$4K
- Amgen$3K
- AbbVie$3K
- Novo Nordisk$2K
- Johnson & Johnson$1K
- plus $18K from 54 others
What the payments were for
- Consulting fees$9753%
- Speaking & faculty fees$6,18617%
- Travel & lodging$8002%
- Food & beverage$28,35277%
- Education$6402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,953 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DovatoDolutegravir Sodium/Lamivudine | 56 | $173,442 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 33 | $152,837 |
| MounjaroTirzepatide | 114 | $144,436 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 31 | $130,325 |
| IsentressRaltegravir Potassium | 51 | $112,459 |
| TivicayDolutegravir Sodium | 46 | $100,838 |
| OzempicSemaglutide | 63 | $89,268 |
| DescovyEmtricitabine/Tenofov Alafenam | 25 | $68,795 |
| EliquisApixaban | 55 | $61,105 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $55,369 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 13 | $48,014 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $46,581 |
| JulucaDolutegravir/Rilpivirine | 11 | $37,932 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $31,457 |
| JatenzoTestosterone Undecanoate | 29 | $31,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Tivicay, Triumeq, Juluca | $3,879 | $360,225126 claims |
| GileadBiktarvy, Descovy, Genvoya | $583 | $254,48968 claims |
| Janssen Products, LPSymtuza | $780 | $152,83733 claims |
| Lilly USA, LLCMounjaro | $460 | $144,436114 claims |
| MerckIsentress, Segluromet | $1,307 | $116,87363 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Trijardy Xr | $1,092 | $97,40585 claims |
| Novo NordiskOzempic | $2,009 | $89,26863 claims |
| PfizerEliquis | $991 | $61,10555 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $424 | $34,95037 claims |
| GSKTrelegy Ellipta | $951 | $31,45728 claims |
| Clarus Therapeutics Inc.Jatenzo | $22 | $31,01229 claims |
| Johnson & JohnsonXarelto | $1,312 | $18,94320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in New Carlisle
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
- Thomas KintanarFort Wayne$185K
- Jeffrey HiltzMuncie$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.